This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In a confirmatory Phase 3 test of ImmunoGen’s Elahere, the ovarian cancer drug handily beat chemotherapy with results that clinicians say could make the treatment the new standard of care for certain patients. The data were presented during the annual meeting of the American Society of Clinical Oncology.
Price transparency has come a long way over the past couple of years, with insurance companies and hospitals now required to publicly disclose their prices. The more pressing issue is that there is no mechanism in place to make this information easily digestible, personalized to each patient, and placed in context with competitors’ prices.
doctor visits, prescription pickups) and enriching our insights with the micro-moments surrounding these obvious events. The Walt Disney Company excels in designing exceptional service because they are hyper-focused on listening, tracking, designing, and measuring the experiences of guests visiting their properties.
As we continue to learn and develop innovative analytics solutions that empower better business, customer, doctor, and patient decisions, this philosophy creates a positive closed loop and drives the analytics learning culture forward. Finally, you worked in both the CPG/Retail and Biopharma industries.
My doctor ordered an MRI, which revealed a five-centimeter tumor on the right side, accompanied by lymph-node involvement. And, what else hasn’t my doctor told me about?” This was several weeks after my very first mammogram–which I underwent shortly after my 40th birthday–detected an anomaly on my left breast.
The company said that it was stopping access to the drug for new patients immediately, while those already taking it would be able to continue on it via a free drug programme, after consultation with their doctors – a move that has garnered praise from across the biopharma industry.
Prior to his work in the biopharma industry, Dr Boshoff was founding Director of the University College London (UCL) Cancer Institute. He earned his medical degree from University of Pretoria in South Africa, a doctorate PhD from the Institute of Cancer Research in London.
Biopharmas and global agencies are now prioritizing initiatives and innovations to drive speed across product development with an emphasis on getting new treatments in the hands of doctors and patients.
Instead of pulling away from the amyloid theory, or going past it, they are now giving it a tremendous boost, despite a mountain of data that proves it’s the wrong path — at least on its own” Ultimately, this is a disaster that will once again create a serious atmosphere of financial toxicity, for everyone in biopharma.
Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. The impact could be huge for the biopharma industry. Novo Nordisk Pharmatech is excited to support the new modalities at the very forefront of the biopharma industry.
However, the biopharma industries realised that traditional vaccine development and manufacturing techniques, which take around five to 10 years for initial development to large-scale distribution, 1 were inadequate to meet the growing demand for COVID-19 vaccines. The future of platform-based vaccine technology and manufacturing.
This “synchronization” helps biopharmas such as Pfizer maximize marketing and field efforts across their organizations to improve engagement with healthcare professionals (HCPs). However, many biopharmas fail to synchronize engagement and digital touchpoints in a timely manner for 73% of HCPs.
When Marc’s doctors discovered he had a rare liver condition, it almost felt like a relief. That’s what doctors are taught, so we can’t be surprised that many patients with a “zebra” condition get the “horse” treatment. It’s also in these communities where biopharma finds the best opportunities to connect with their stakeholders.
With no specific medication available, doctors are likely to recommend exercise and self-management of the condition, through rest and reduced workload. Anyone living with Long COVID would likely be interested in knowing why the same urgency is not being shown to develop a treatment for this condition.
There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).
billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. He attended the College of the Holy Cross studying Mathematics and Physics and went on to receive his doctorate from the University of Arizona in Applied Mathematics under Professor Harrison H.
Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients.
I recently sat down with Erica Taylor, PhD, Vice President and Chief Marketing Officer at Genentech, to talk about the future of biopharma marketing and creating more meaningful content.
The company has long argued that the current need to use multiple meningococcal vaccines to provide coverage has resulted in confusion among consumers and doctors, leading to poor compliance and low sales.
One step in this direction is DrugGPT, a tool that has been rolled out to doctors in the UK. Yet from a risk-mitigation perspective, we anticipate a cautious, measured approach by most biopharma companies. It provides guidance and acts as a safety net for prescribers. In the patient engagement space, the potential is immense.
This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Those of us in the biopharma industry know how fraught drug development can be. As the saying goes, they are individually rare but collectively common. Many people, cumulatively, are affected.
He also explored how to create equitable access to advanced AI-based diagnostics and treatment pathways, how biopharma companies can leverage federated learning to overcome the challenges of accessing real-world data, and more. They could have the ability to rediscover their identity by a hospital based on need.
His areas of focus are R&D acceleration, commercial excellence, creating engaging digital experiences for patients, doctors and pharmacists, and running the business more efficiently. Brendan O’Callaghan leads an international network of manufacturing sites.
FiercePharma: The drive to digital in pharma marketing is overwhelming doctors, 2022hys.org/news/2024-06-surveyperception-scientists-credibility.html This synergy has deepened the connection between Sales and Marketing in the Life Sciences industry, with HCPs at the center. Veeva Pulse Field Trends Report, 2023 2.
Patients are most active searching for online health information when preparing for a doctor visit, when 19% do so; after a doctor’s appointment (20%); and after receiving a prescription but before getting it filled (19%).More More patients are using both pharma and third-party online info sources.
Veeva OpenData provides additional insight into registrars and new doctors. Some of the largest pharmaceutical companies in the world, as well as emerging biopharma, use Veeva OpenData to increase field force effectiveness, boost productivity and enhance customer engagement. 43% said they do not have robust data management processes.
For some patients, pandemic-related disruptions have perhaps meant an elective surgery deferred or a follow-up doctor visit done through an app rather than in person. patients were asked how they saw their use of virtual doctor visits changing once pandemic mitigation measures have lifted. In a recent Clarivate survey, U.S.
Veradigm provides biopharma marketers an opportunity to deliver awareness messages directly to the HCPs of interest, during their point of care workflow. No biopharma or device advertisements appear during the prescribing workflow. Try Veradigm Digital Health Media for Highly Targeted Messages.
While I like traditional blinded market research projects or online virtual panels, the participants tend to be the “engaged patients” and may not account for the doctor-dependent patients needed to reach to move the market. However, I don’t believe there is, or should be, only one way of gathering patient feedback.
I worked as a hospital doctor for several years and then as a GP for several years, and it became very apparent that there was not enough information for patients to help them to better understand their illnesses, better understand their treatment [and] what to do with their medications. Dr. Grace Lomax : Yes, happily.
Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses. VMS biopharma clients expect them to move quickly — and to do so, the company saw an opportunity to streamline processes, drive efficiencies, and make it more seamless for its team to work together. .
I think one of the mistakes that we made collectively is assuming that with telehealth, we can just turn on a switch and everybody’s going to access the internet and start to see their doctor. That’s not necessarily true. Through telehealth, more barriers became more apparent. “I That’s not necessarily true.”.
After earning his MSc in Chemistry, he worked at the Robert Koch Institute in Berlin (German Federal Health Office) and completed his doctorate at Berlin Free University. Biopharma successful in achieving climate-related goals, report finds … . Hoffmann-La Roche Ltd based in Basel, Switzerland. Ramboll website.
His career has spanned various roles including brand protection utilising novel technologies at De La Rue, to numerous QC, scientist and project management roles in Eli Lilly, Patheon (now Thermo Fisher), Catalent and Porton Biopharma. Neil obtained a degree in medicinal and pharmaceutical chemistry from Loughborough University.
She has a particular interest and expertise in immuno-oncology and received her doctorate from the University of Oxford. Rachel has more than a decade of experience in market forecasting and a broad knowledge of oncology indications and markets.
Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Typically, we think of patient partnerships in terms of their external impact—for example, to help educate doctors and payers. Different patients have unique needs. Anthony Yanni.
As you know, you couldn’t go and see your doctor in the clinic. That was a classic example where their business really boomed because of that type of activity.The other area was that, we were investors in MD Live, which is the second-largest telehealth company. They really came into their own last year with that scope of activity.
New York Governor Kathy Hochul signed new legislation that will protect the state’s doctors, medical providers and facilitators who prescribe abortion care telehealth services to patients outside of New York from litigation in states where abortion services are banned or restricted.
For example, a biopharma may want to track the improvement in patient adherence to a therapy pre- and post-launch of a PSP across regions to gauge its impact. A system that connects patients with their entire care team—doctors, specialists, therapists—ensures everyone is on the same page. Our programs can be the map that guides them.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content